Small‑cell lung carcinoma transformation of lung adenocarcinoma diagnosed by pericardial effusion: A case report

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 361:947–957. 2009.PubMed/NCBI View Article : Google Scholar

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 19:2240–2247. 2013.PubMed/NCBI View Article : Google Scholar

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3(75ra26)2011.PubMed/NCBI View Article : Google Scholar

Minari R, Bordi P, Del Re M, Facchinetti F, Mazzoni F, Barbieri F, Camerini A, Comin CE, Gnetti L, Azzoni C, et al: Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy. Lung Cancer. 115:21–27. 2018.PubMed/NCBI View Article : Google Scholar

Iijima Y, Hirotsu Y, Mochizuki H, Amemiya K, Oyama T, Uchida Y, Kobayashi Y, Tsutsui T, Kakizaki Y, Miyashita Y and Omata M: Dynamic changes and drug-induced selection of resistant clones in a patient with EGFR-mutated adenocarcinoma that acquired T790M mutation and transformed to small-cell lung cancer. Clin Lung Cancer. 19:e843–e847. 2018.PubMed/NCBI View Article : Google Scholar

Taniguchi Y, Horiuchi H, Morikawa T and Usui K: Small-cell carcinoma transformation of pulmonary adenocarcinoma after osimertinib treatment: A case report. Case Rep Oncol. 11:323–329. 2018.PubMed/NCBI View Article : Google Scholar

Kim TM, Song A, Kim DW, Kim S, Ahn YO, Keam B, Jeon YK, Lee SH, Chung DH and Heo DS: Mechanisms of acquired resistance to AZD9291: A mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 10:1736–1744. 2015.PubMed/NCBI View Article : Google Scholar

Ham JS, Kim S, Kim HK, Byeon S, Sun JM, Lee SH, Ahn JS, Park K, Choi YL, Han J, et al: Two cases of small cell lung cancer transformation from EGFR mutant adenocarcinoma during AZD9291 treatment. J Thorac Oncol. 11:e1–e4. 2016.PubMed/NCBI View Article : Google Scholar

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, et al: Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 378:113–125. 2018.PubMed/NCBI View Article : Google Scholar

Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, et al: EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: Clinical outcomes. J Clin Oncol. 37:278–285. 2019.PubMed/NCBI View Article : Google Scholar

Oser MG, Niederst MJ, Sequist LV and Engelman JA: Transformation from non-small-cell lung cancer to small-cell lung cancer: Molecular drivers and cells of origin. Lancet Oncol. 16:e165–e172. 2015.PubMed/NCBI View Article : Google Scholar

Hayano M, Hokamura Y, Kimura Y, Kimura T and Tokube K: Clinical studies of 16 cases of carcinomatous pericarditis. Kokyu To Junkan. 39:683–686. 1991.PubMed/NCBI(In Japanese).

Wang PC, Yang KY, Chao JY, Liu JM, Perng RP and Yen SH: Prognostic role of pericardial fluid cytology in cardiac tamponade associated with non-small cell lung cancer. Chest. 118:744–749. 2000.PubMed/NCBI View Article : Google Scholar

Kato R, Hayashi H, Chiba Y, Tanaka K, Takeda M and Nakagawa K: Prognostic impact of minimal pericardial effusion in patients with advanced non-small-cell lung cancer. Clin Lung Cancer. 18:e449–e455. 2017.PubMed/NCBI View Article : Google Scholar